NuPeak Therapeutics, Inc.

Saint Louis, MO · Biotech · Private

Small-molecule kinase inhibitor (SMKI) targeting MAPK for treatment of asthma and COPD

Grants
$2.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A New Small-Molecule Kinase Inhibitor for Breast Cancer$300,000
Federal grantDepartment of Health and Human Services · Phase I · A New Small-Molecule Kinase Inhibitor for Airway Disease$300,000
Federal grantDepartment of Health and Human Services · Phase II · A New Small-Molecule Kinase Inhibitor for Airway Disease$1,018,383
Federal grantDepartment of Health and Human Services · Phase II · A New Small-Molecule Kinase Inhibitor for Airway Disease$1,019,816
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2979Navire Pharma——
2980POW GENETIC SOLUTIONS, INC.——
2981QUORUM INNOVATIONS, LLC——
2982NuPeak Therapeutics, Inc.——
2983SINGULAR IMMUNE, INC.——
2984GLOW THERAPEUTICS INC.——
2985TIGATX INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.